when

Latest
Archive

by source

All Sources
Sources Page

department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Jobs
News

Hubs

Topics
Patent cliff
Publications

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
search

Immunology · news · pharmadog

← back to Immunology

News · Immunology

413 stories

May 8, 26OncLive Polls Reveal Picks for Top Lung Cancer Abstracts at ASCO 2026onclive

May 8, 26Poll Results Highlight Breast Cancer Abstracts of Interest at ASCO 2026onclive

May 8, 26Lilly, Gilead lead pharma’s M&A boombiopharma dive

May 8, 26Dr Gruenbaum on Where Alternative Options to BTK Inhibitors Stand in MCLonclive

May 8, 26Odyssey raises more than $300M as biotech goes publicendpoints

May 8, 26Odyssey, on second try, snags $279M in an IPObiopharma dive

May 7, 26Dr Sznol on Optimal Treatment Sequencing in Melanomaonclive

May 7, 26Dr Mauro on the Significance of Alternative TKI Formulations in CMLonclive

May 7, 26Dr Olawaiye on the FDA Approval of Relacorilant Plus Nab-Paclitaxel in PROConclive

May 7, 26Sylvester Comprehensive Cancer Center Identifies a Screening Gap to Prevent a Type of Leukemia in the U.S.onclive

May 7, 26ASCO 2026 TNBC Deep Dive: Breast Cancer Experts Preview Practice-Informing Studiesonclive

May 7, 26Angelini to buy Catalyst in $4B play for rare neuro drugsbiopharma dive

May 7, 26Track the Lung Cancer Abstracts That are Gaining Attention at ASCO 2026onclive

May 7, 26Reigniting Your Curiosity During Fellowshiponclive

May 6, 26Dr McGregor on the DAD-IO Trial of Sacituzumab Govitecan and EV in Metastatic Urothelial Carcinomaonclive

May 6, 26Neoadjuvant T-DXd Followed by THP Improves RCB in HER2+ Breast Canceronclive

May 6, 26Dr Lee on Research Collaborations Studying PD-L1 as a Biomarker in NSCLConclive

May 6, 26Dr Chari on Frontline Combinations and Transplant Approaches in Multiple Myelomaonclive

May 6, 26BeOne culls five cancer programs and an autoimmune Phase 2endpoints

May 6, 26Cases and Conversations™: Next-Generation Pathology Advances and Considerations for Precision Care in Non–Small Cell Lung Canceronclive

May 6, 26Dr Herrera on the Significance of the FDA Approval of Nivolumab Plus AVD for Classical Hodgkin Lymphomaonclive

May 6, 26Dr Sznol on Biomarkers of Response in Metastatic Melanomaonclive

May 6, 26Transformational Utah Investment in Artificial Intelligence and Computing to Advance Health and Discoveryonclive

May 6, 26STAT+: Color Health moving deeper into cancer services, complete with virtual ‘tumor boards’stat

May 6, 26Avalo scores Phase 2 success in comeback bid, raises $375Mendpoints

May 6, 26STAT+: How a global effort to explore the ‘dark proteome’ is upending our understanding of human diseasestat

May 6, 26ASCO 2026 HR+ and HER2+ Breast Cancer Preview: Read up on the Insights to Know Before You Goonclive

May 6, 26STAT+: Novo Nordisk’s less-bad news on its Wegovy pill boosts earnings and share pricestat

May 6, 26Disease Assessment and Mutational Testing in Progressive CLLonclive

May 6, 26Clinical Scenario Presentation and Treatment Approach for Progressive Diseaseonclive

← prevpage 12 of 14next →